<?xml version="1.0" encoding="UTF-8"?>
<p id="Par18">Currently, more than 80 clinical trials have been registered in the Chinese Clinical Registry to test for a coronavirus treatment. During the first week of February, China launched two placebo-controlled trials of remdesivir, slated to include 760 people with COVID-19. The studies should be completed by the end of April, 2020. A few trials have started to test chloroquine, an antimalarial drug that killed off the SARS-CoV-2 in cell cultures. Researchers are studying whether steroids diminish inflammation in people with severe COVID-19, or cause harm. Another 300-person controlled trial is aimed to test whether serum antibodies from COVID-19 survivors could rapidly help someone newly infected with the SARS-CoV-2 virus. Fifteen trials listed in Chinaâ€™s registry expect to enroll a total of more than 2,000 people in studies on a variety of TCMs, including the largest trial assessing 
 <italic>Shuanghuanglian</italic> with 400 participants [
 <xref ref-type="bibr" rid="CR15">15</xref>].
</p>
